Home › Companies › GUTS

Fractyl Health

Market cap $12.8M 13.3M shares (10-Q, Nov 2, 2026) × $0.965 close Nov 17, 2026

Most recent annual filing: 2026-01-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Fractyl corporate financing4Q 2026/1Q 2027Fractyl corporate financing, 4Q 2026/1Q 2027, routine
  2. Revita filinglate 4Q 2026Revita filing, late 4Q 2026, notable
  3. Revita pivotal topline1Q 2027Revita pivotal topline, 1Q 2027, major
  4. 2023 Notes covenant corporate updatelate 1Q 20272023 Notes covenant corporate update, late 1Q 2027, routine
  5. Company-wide corporate update2Q 2027Company-wide corporate update, 2Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Technology platforms

Rejuva

AAV-delivered pancreatic gene therapy platform designed to enable long-term remission of T2D and obesity by durably reprogramming pancreatic islet cells to endogenously produce metabolic hormones (GLP-1, GIP, PYY, amylin, glucagon). Modular platform using AAV9 vectors with tissue-restricted insulin promoter-driven transgene expression, delivered via proprietary endoscopic device directly to the pancreas.

Targets: GLP-1, GIP, PYY, amylin

Discontinued (3)

Capital (as filed)

Cash
$31.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$15.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$31.5M cash, runway Q2 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (13)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (13 calls)

Every verdict Biotech Distilled has published on Fractyl Health, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative Fractyl Health (GUTS): Scientific Deep Dive for Revita® and Rejuva® Strong mechanistic proof-of-concept and cleared financing overhang create favorable risk/reward for the next 12 months ahead of binary 2026 catalysts.
  2. Buy speculative UPDATE: Fractyl Health (GUTS) - The Mixed Data Crash (6-Mo Readout) The 70% stock drop appears to be an overreaction to small-n statistical noise; the underlying biology in the High Responder target group remains intact (p=0.004) and the company is financed through the H2 2026 pivotal readout.
  3. Buy core UPDATE: Fractyl Health (GUTS) - The Clock is Set Completion of REMAIN-1 randomization removes trial execution risk and confirms the company is funded through the early Q4 2026 pivotal readout without a dilutive raise.
  4. Buy core UPDATES: Fractyl Health (GUTS) - Insiders Buys CEO and CFO buying a combined 350,000 shares at $0.55–$0.57 on the day the trading window opened post-earnings signals strong insider conviction that the January sell-off was a structural overreaction, not a fundamental failure.
  5. Buy core UPDATE: Fractyl Health (GUTS) - The Moonshot Gets a Clinic Dutch CTA clearance for RJVA-001 confirms the gene therapy pipeline has real clinical optionality, the H2 2026 catalyst slate is now two-headed, and management pre-empted dilution fears by confirming Rejuva development is funded within existing runway.
  6. Buy core UPDATE: Fractyl Health (GUTS) - The Durability Question, Answered REVEAL-1 12-month open-label data showing 100% of patients above the pivotal's responder threshold and ~78% of GLP-1 weight loss retained answers the durability question and provides a concrete read-through to the Q4 pivotal co-primary endpoint.
  7. Buy core UPDATE: Fractyl Health (GUTS) - The Durability Question, Answered (Randomized Edition) Randomized 12-month REMAIN-1 Midpoint data confirms durable efficacy with a dose-response gradient, and favorable FDA De Novo feedback materially de-risks the regulatory pathway ahead of the early Q4 pivotal readout.
  8. Speculative buy speculative UPDATE: Fractyl Health (GUTS) - The Going Concern Arrives The formal going-concern qualification and $10M loan covenant floor shift the balance sheet from 'adequate' to 'adequate only if the data lands,' warranting a downgrade to speculative while the clinical thesis remains intact.
  9. Speculative buy speculative UPDATE: Fractyl Health (GUTS) - The September 9 Deadline Came and Went The Nasdaq delisting is stayed by a Panel hearing request, keeping shares trading through the pivotal readout window, but a near-certain reverse split raises the bar for the Tranche B warrant financing and the position remains a lottery-ticket-sized bet.
  10. Speculative buy speculative UPDATE: Fractyl Health (GUTS) - The Split Is Locked The 1-for-12 reverse split is confirmed and largely cosmetic, the pivotal readout window has opened, and the ~$71M market cap against an estimated ~$28M cash prices in substantial failure risk while the science remains unchanged.
  11. Hold UPDATE: Fractyl Health (GUTS) - The Pivotal Hit. The Stock Imploded. The pivotal co-primary was met (p=0.0023) validating the mechanism, but the effect size came in at roughly half of what Midpoint implied and the balance sheet now outranks the biology — existing holders should wait to see who writes the financing check and on what terms before acting.
  12. Hold UPDATE: Fractyl Health (GUTS) - The Moonshot Gets Cut Dropping Rejuva and cutting 45% of staff halves the burn rate and extends runway past the 12-month readout, but a raise before launch still looks unavoidable and new money is better served waiting for the financing to set the dilution.
  13. Avoid UPDATE: Fractyl Health (GUTS) - The Covenant Clock Beats the Data Clock The loan covenant could breach by end of Q1 2027 — the same quarter as the 12-month readout — placing the secured lender ahead of common shareholders, the reverse split failed to cure Nasdaq compliance, and stockholders' equity is negative, making the capital structure the dominant risk for new and existing holders.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (36)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)